Abstract

Abstract Background: despite the profound rarity of breast cancer in males, it remains of importance given the associated morbidity and mortality, including the association with worse prognosis than female patients. Nonetheless, male breast cancer epidemiology remains poorly studied in middle eastern populations. Methodology: This retrospective cohort study examined male patients aged 15 to 85 years who were diagnosed with breast cancer between 2000 and 2018, using data from the Jordan Cancer Registry. Kaplan-Meier analysis was performed to assess the 5-year overall survival of the patients over time. Results: A total of 22,600 patients were diagnosed with breast cancer since 2000 in Jordan, of which 362 (1.6%) patients were males. 39.8% of male breast cancer cases occurred in the right breast, while the left breast was affected in 43.4% of the cases, and 3.3% of the cases were bilateral. Meanwhile, laterality was not mentioned in 13.5% of registry records. All male breast cancer cases were malignant in origin with the breast being the primary cancer. Most male patients had grade II (N=112, 30.9%) followed by grade III breast cancer (N=88, 24.3%). Among the male breast cancer cohort, 224 (62.2%) were treated with surgical intervention, 103 (28.8%) patients were given chemotherapy, 84 (23.4%) patients had radiotherapy and 24 (6.70%) patients had hormonal therapy. 27 patients died during the follow up period. The 5-year overall survival rate for the patients was 92.5% (95% CI, 89.9% to 95.3%). Conclusion: Breast cancer in middle eastern males tends to more commonly present in the left breast, and at a more advanced stage in comparison to females. Citation Format: Zaid Abdulelah, Ahmed Abdulelah, Abdulrahman Alhajahjeh, Ahmad Ghazzawi, Layla El-Amayreh, Hikmat Abdel-Razeq. Epidemiological Analysis and Overall Survival of Male Breast Cancer in a Developing Middle Eastern Country Over 18 Years [abstract]. In: Proceedings of the 2023 San Antonio Breast Cancer Symposium; 2023 Dec 5-9; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2024;84(9 Suppl):Abstract nr PO4-17-09.

Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.